Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy

Journal of Infectious Diseases

Volumn 209, Issue 8, 2014, Pages 1156-1164

  Eckard, Allison Ross ^a,b   Jiang, Ying ^c   Debanne, Sara M ^c   Funderburg, Nicholas T ^c,d   Mccomsey, Grace A ^c,d,e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

cardiovascular disease; coagulation; HIV; inflammation; statin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ABACAVIR; C REACTIVE PROTEIN; CD38 ANTIGEN; D DIMER; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FIBRINOGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DR ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARAVIROC; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION;

CARDIOVASCULAR DISEASE; COAGULATION; HIV; INFLAMMATION; LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2; STATIN;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; REGRESSION ANALYSIS; RISK FACTORS; SULFONAMIDES; TREATMENT OUTCOME; VASCULITIS;

EID: 84897447775     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiu012     Document Type: Conference Paper

References (50)

1. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-12.
2. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-Association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-93.
3. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: Carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23:1841-9.
4. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119-27.
5. Kuller LH, Tracy R, BellosoW, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
6. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51:268-73.
7. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PloS One 2012; 7: E44454.
8. Longenecker C, Funderburg N, Jiang Y, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013; 14:385-90.
9. Hsue PY, Scherzer R, Hunt PW, et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc 2012; 1.:jah3-e000422.
10. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009; 203:325-30.
11. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96:24F-33F.
12. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-8.
13. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38.
14. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 2009; 373:1175-82.
15. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207.
16. Calza L, Trapani F, Bartoletti M, et al. Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factoralpha in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials 2012; 13:153-61.
17. Amar J, Fauvel J, Drouet L, et al. Interleukin 6 is associated with subclinical atherosclerosis: A link with soluble intercellular adhesion molecule 1. J Hypertens 2006; 24:1083-8.
18. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599-610.
19. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-Alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-53.
20. Hileman CO, Longenecker CT, Carman TL, et al. Elevated D-dimer is independently associated with endothelial dysfunction: A cross-sectional study in HIV-infected adults on antiretroviral therapy. Antivir Ther 2012; 17:1345-9.
21. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-Analysis. JAMA 2005; 294:1799-809.
22. Vittos O, Toana B, Vittos A, Moldoveanu E. Lipoprotein-Associated phospholipase A2 (Lp-PLA2): A review of its role and significance as a cardiovascular biomarker. Biomarkers 2012; 17:289-302.
23. Thompson A, Gao P, Orfei L, et al. Lipoprotein-Associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536-44.
24. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-Associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005; 26:137-44.
25. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity Creactive protein, lipoprotein-Associated phospholipase A2, and outcome after ischemic stroke. Arch Int Med 2006; 166:2073-80.
26. Sabatine MS, Morrow DA, O'Donoghue M, et al. Prognostic utility of lipoprotein-Associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007; 27:2463-9.
27. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-8.
28. Greenland P, Alpert JS, Beller GA, et al
29. Zalewski A, Macphee C. Role of lipoprotein-Associated phospholipase A2 in atherosclerosis: Biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25:923-31.
30. KoenigW, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-Associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middleaged men from the general population: Results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004; 110:1903-8.
31. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-Associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008; 101:51F-7F.
32. Braun LT, Davidson MH. Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep 2010; 12:29-33.
33. Schaefer EJ, McNamara JR, Asztalos BF, et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-Associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 2005; 95:1025-32.
34. Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypolipidemic drugs on lipoprotein-Associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007; 27:2236-43.
35. Reddy KJ, Singh M, Batsell RR, Bangit JR, Miraskar RA, Zaheer MS. Lipoprotein-Associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy. Prev Cardiol 2010; 13:130-4.
36. Lee SH, Kang SM, Park S, Jang Y, Chung N, Choi D. The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-Associated phospholipase A(2). Clin Cardiol 2011; 34:108-12.
37. Song JX, Ren JY, Chen H. Simvastatin reduces lipoprotein-Associated phospholipase A2 in lipopolysaccharide-stimulated human monocytederivedmacrophages through inhibition of themevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-Activated protein kinase pathway. J Cardiovasc Pharmacol 2011; 57:213-22.
38. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention?. Am J Cardiol 2006; 97:33A-41A.
39. Dohi T, Miyauchi K, Okazaki S, et al. Decreased circulating lipoproteinassociated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome. Atherosclerosis 2011; 219:907-12.
40. Qiao Z, Ren J, Chen H. Simvastatin reduces expression and activity of lipoprotein-Associated phospholipase A(2) in the aorta of hypercholesterolaemic atherosclerotic rabbits. J Internat Med Res 2009; 37:1029-37.
41. Ho JE, Deeks SG, Hecht FM, et al. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2010; 24:1897-905.
42. Ho JE, Scherzer R, Hecht FM, et al. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS 2012; 26:1115-20.
43. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-8.
44. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51:435-47.
45. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010; 55:615-9.
46. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-504.
47. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-35.
48. Ridker PM, MacFadyen JG, Wolfert RL, Koenig W. Relationship of lipoprotein-Associated phospholipase A(2) mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: An analysis from the JUPITER trial. Clin chem 2012; 58:877-86.
49. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011; 203:452-63.
50. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39:633-45.